key: cord-0776861-31fqjp9v
authors: Godino, Cosmo; Scotti, Andrea; Maugeri, Norma; Mancini, Nicasio; Fominskiy, Evgeny; Margonato, Alberto; Landoni, Giovanni
title: Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence-
date: 2020-09-28
journal: Int J Cardiol
DOI: 10.1016/j.ijcard.2020.09.064
sha: b9a570e5c6eaabe1e278cd9dc027e501b069f113
doc_id: 776861
cord_uid: 31fqjp9v

In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly evident as the final step of pro-inflammatory cytokines storm. Actually, no proven effective therapies for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection exist. Preliminary observations on anticoagulant therapy appear to be associated with better outcomes in moderate and severe COVID-19 patients with signs of coagulopathy and in those requiring mechanical ventilation. The pathophysiology underlying the prothrombotic state elicited by SARS-CoV-2 outlines possible protective mechanisms of antithrombotic therapy (in primis anticoagulants) for this viral illness. The indications for antiplatelet/anticoagulant use (prevention, prophylaxis, therapy) are guided by the clinical context and the COVID-19 severity. We provide a practical approach on antithrombotic therapy management for COVID-19 patients from a multidisciplinary point of view.

Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation ranges between mild-to-moderate illness (~80% of cases) to severe (~15%) or critical (~5%) conditions. [1, 2] The pathogenic pathways of SARS-CoV2 are not fully understood yet. In patients with disease progression, COVID-19 meets the criteria for acute respiratory distress syndrome (ARDS) with hyperimmune host reaction. [2, 3] The mechanism of lung damage can be primarily explained by initial virus-induced direct damage involving both type I and type II pneumocytes [4] and alveolar endothelial cells, [5, 6] followed by uncontrolled severe inflammatory reaction and microvascular pulmonary thrombosis. [7, 8] After managing more than 800 cases of severe pneumonia and more than 120 invasively ventilated patients in our Hospital, [9, 10] we suggested the pathophysiological hypothesis of the thromboinflammatory syndrome, as recently reported with the acronym MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome). [11] Although SARS-COV-2 has tropism for ACE2-expressing epithelial cells of the respiratory tract, other co-receptors are probably involved in viral entry, and patients with severe COVID-19 have symptoms of systemic hyperinflammation and endothelial damage with microvascular thrombosis also involving the microvascular bed of the heart, [12] kidneys, brain [13] and other organs. [14] As this infection is novel, no proven effective therapies for COVID-19 currently exist, and tremendous efforts are made to identify a specific escalation therapy according to the clinical presentation. SARS-CoV-19 is a betacoronavirus, as are severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Drugs such as remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine and corticosteroids, have been used in patients with COVID-19, and before against SARS or MERS, showing controversial efficacy. Actually, medical therapies to prevent the effects of the coagulopathy observed in these patients have been suggested for COVID-19.

[15] Preliminary data on anticoagulant therapy appear to be associated with better outcomes in moderate and severe COVID-19 patients with signs of coagulopathy J o u r n a l P r e -p r o o f Journal Pre-proof (elevated D-dimer and fibrinogen and low anti-thrombin levels), [16, 17] and in those requiring mechanical ventilation. [18] Such treatment can improve the coagulation dysfunction and also exert anti-inflammatory effects by reducing IL-6 and increasing the relative count of lymphocytes. [19] We highlight the pathophysiology underlying the prothrombotic state elicited by SARS-CoV-2 infection, present the proper studies investigating antithrombotic therapy in several virus infections, and focus on possible protective mechanisms of antithrombotic therapy (in primis anticoagulants) for COVID-19 treatment and need for future studies.

There is evidence that hospitalized COVID-19 patients often suffer from an important infectionrelated coagulopathy and from elevated risks of microvascular thrombosis. [1, 14, 17, 20] Anticoagulants may have positive effects here, reducing the burden of thrombotic disease and the hyperactivity of coagulation, and may also hold beneficial direct anti-inflammatory effects against sepsis and the development of ARDS. It is known that heparins, including unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), have several non-anticoagulant properties, and can exert anti-inflammatory effects. Indeed heparins block P-selectin, the cross-talk of platelets and [29] Heparan sulfate has been known to work as the initial point of contact between target cells and several human viruses (i.e., herpesviruses, influenza A virus, hepatitis C virus, human immunodeficiency virus, dengue), [30] [31] [32] [33] [34] including the SARS-CoV-2. [35] Heparins have been shown to efficiently compete with heparan sulfate and by that attenuate viral attachment and cell infection.

Moreover, SARS-CoV2 is characterized by the presence of several Spike (S) proteins projecting from the virion surface. Each S protein is formed by two subunits (S1 and S2). The S1

subunit features the receptor binding domain that interacts with the main host cell receptor, angiotensin-converting enzyme 2 (ACE2) receptor. Recently, it was reported that the SARS-CoV-2 S1 receptor binding domain is bound by heparin and that, upon binding, a significant structural change is induced, providing forthright evidence for a direct antiviral effect of LMWH in patients with COVID-19. [35] These mechanisms are not the only ones! The S1-ACE-2 binding is only the first step of infection. The entrance of the SARS-CoV-2 into the human cell needs the cleavage of S1-S2 subunits to expose S2 for adhesion to cell membrane. [36, 37] The cellular proteases, cell surface transmembrane protease/serine (TMPRSS) proteases, including cathepsins, factor Xa, furin, trypsin (most of them inhibited by heparin [38] ) have been shown to proteolytically process the spike protein. In particular, the factor Xa has been shown to facilitate the activation of SARS-CoV entry

Until today, unlike anticoagulant therapy, no clinical observations were reported regarding possible protective or therapeutic effects of antiplatelet therapy in COVID-19. Notwithstanding, a pathophysiological rationale for theoretical benefits exists. SARS-CoV-2 infects the endothelial cells using the ACE-2 receptors, which are widely expressed on vascular beds of different organs (kidney, heart, brain, intestine and liver). [12, 13] Post-mortem histology revealed typical lymphocytic endotheliitis as a direct consequence of SARS-CoV-2 infection, which led to diffuse endothelial inflammation and dysfunction. [5] The endothelial dysfunction favours a shift of the haemostatic balance towards procoagulant state, triggering platelet adhesion and aggregation [41] and thereby initiating a thromboinflammatory process (Central Illustration). In several tissue injury to platelet activation and the expression of a highly thrombotic phenotype of platelets since this stimulus induce the expression of biologically active tissue factor on platelet surface. [50] In animal models, platelet activation promoted influenza A virus pathogenesis by sustaining severe inflammatory response in the respiratory system. Activating protease-activated receptor 4 (a platelet receptor for thrombin that is crucial for platelet activation) exacerbated influenza-induced acute lung injury and death mostly at late postinfection time points. In contrast, treatment with Eptifibatide (specific antagonist of glycoprotein IIb/IIIa), antagonists of protease-activated receptor J o u r n a l P r e -p r o o f Journal Pre-proof 4 , and Clopidogrel (inhibitors of the adenosine diphosphate receptors P2Y1 and P2Y12) showed protective effects for severe lung injury (inhibition neutrophil recruitment into inflamed lungs) and lethal infections induced by several influenza strains. [51] These results are consistent with other studies showing that aspirin blocks influenza A virus propagation via nuclear factor-kB inhibition, [52] and diminishes immune activation in HIV-1 patients. [53, 54] Recurrent outbreaks that cause severe infections in humans (influenza A virus subtypes, SARS, MERS etc.) have raised concerns regarding therapeutic strategies available for these pathogens. Current treatments that target viral proteins have a number of disadvantages, including the rapid development of resistant virus variants (especially for RNA virus). [55, 56] Targeting the host rather than the virus with drugs regulating thromboinflammation can be a potential strategy for new therapeutics of recurrent outbreaks. Therefore, there is a rationale behind trying specific therapies to stabilise the endothelium and platelets during viral replication, especially with antiplatelet therapy as well as with anti-inflammatory (corticosteroids) and anti-cytokine drugs (ie. tocilizumab, anakinra, reparixin, canakinumab, interleukin-1β inhibitor, and interferon-β1). [57] [58] [59] During the actual pandemic of COVID-19, in the absence of validate therapies and overwhelming disease, in several hospitals, many physicians have been attempting novel therapies in order to mitigate the disease. The attempt to apply new therapeutic strategies comes from the awareness that it will take a long time before scientific studies can validate specific therapies in the face of an urgent need to save patients' lives. Even the chloroquine and the hydroxychloroquine (antimalarial drugs) were empirically utilized to treat patients mostly with mild or moderate symptoms, [60] and have demonstrated in-vitro efficacy against COVID-19 by an as yet not fully understood mechanism. [61, 62] Preclinical studies have suggested that hydroxychloroquine has antiplatelet properties possibly through the interaction with arachidonic acid (AA) pathway (downstream to thromboxane A2 production) and the reduction of fibrinogen levels. [63, 64] J o u r n a l P r e -p r o o f Journal Pre-proof Further explorations are required to determine the degree of platelet activation that is present in COVID-19 patients. In addition, it will be useful to investigate on preventive role of chronic antiplatelet therapy (single or double) on degree of viremia and disease manifestation.

At the moment, there is no solid scientific evidence on antithrombotic treatment for COVID-19 and further prospective investigations are warranted. Table 1 -VTE risk assessment should precede the adoption of pharmacological prophylaxis or intermittent pneumatic compression in moderate/severe COVID-19; [67] when these forms are complicated by disseminated intravascular coagulation a prophylactic anticoagulation is needed. [16] When there is a clinical condition (i.e. atrial fibrillation, deep venous thrombosis/pulmonary embolism, prosthetic valve) that represents an indication for anticoagulation:

-in patients with mild COVID-19, the usual therapy should be continued; direct oral anticoagulants or LMWH may be considered in case of unstable INR or difficulties in monitoring this parameter (i.e. quarantine, limited access to peripheral laboratories).

-in moderate/severe COVID-19 manifestations anticoagulation therapy may be switched to LMWH or UFH in the presence of clinical deterioration, haemodynamic instability or drugdrug interactions.

In any case, individual evaluation of baseline characteristics (i.e. weight), bleeding and thrombotic risk should be considered for antithrombotic dose reduction or drug's discontinuation.

The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical Characteristics of Coronavirus Disease 2019 in China

Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Endothelial cell infection and endotheliitis in COVID-19

Alarmins and immunity

Preventing COVID-19-induced pneumonia with anti-cytokine therapy

Fast reshaping of intensive care unit facilities in a large metropolitan

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

COVID-19 and the cardiovascular system

Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study

Critically Ill COVID-19 of thrombotic complications in critically ill ICU patients with COVID-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19

The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study

Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell

Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β IL-6 and IL-8

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in

Clinical Features of 69 Cases with Coronavirus Disease

Molecular diversity of heparan sulfate

Herpes Simplex Virus Types 1 and 2 Differ in Their Interaction with Heparan Sulfate

Coronaviridae and SARS-associated Coronavirus Strain HSR1, Emerg. Inhibition of influenza H5N1 invasion by modified heparin derivatives

Dengue virus binding and replication by platelets

The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding

COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity

Heparin enhances serpin inhibition of the cysteine protease cathepsin L

Endothelial cell control of thrombosis, BMC Cardiovasc. Phagocytose vs make neutrophil extracellular traps

Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS), Microbes Infect

Platelet Activation and Apoptosis Modulate Monocyte Inflammatory Responses in Dengue

Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the β2-integrin CD11b/CD18

Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice

Platelet-neutrophil-interactions: Linking hemostasis and inflammation

Src family kinases mediate neutrophil adhesion to adherent platelets

Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis

Platelet activation and aggregation promote lung inflammation and J o u r n a l P r e -p r o o f influenza virus pathogenesis

Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-κB-inhibiting activity

Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: A pilot study

HIV infection and coronary heart disease: An intersection of epidemics

Increased virulence of neuraminidase inhibitorresistant pandemic H1N1 virus in mice: Potential emergence of drugresistant and virulent variants

Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza Viruses

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

Type 1 interferons as a potential treatment against COVID-19

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy

Of chloroquine and COVID-19

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point : Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit

Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: A proof of concept study

On the inhibitory effect of chloroquine on blood platelet aggregation

ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19